Transport characteristics of a novel peptide platform for CNS therapeutics

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 12, 2010, Pages 2827-2839

  Bertrand, Yanick ^a   Currie, Jean Christophe ^a   Demeule, Michel ^b   Régina, Anthony ^b   Ché, Christian ^b   Abulrob, Abedelnasser ^c   Fatehi, Dorothy ^c   Sartelet, Hervé ^d   Gabathuler, Reinhard ^b   Castaigne, Jean Paul ^b   Stanimirovic, Danica ^c   Béliveau, Richard ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b ANGIOCHEM INC   (Canada)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Angiopeps; Blood brain barrier; Brain disease; Drug delivery; Low density lipoprotein receptor related protein 1; Receptor mediated transcytosis; Therapeutics

Indexed keywords

ANGIOPEP 2; ANGIOPEP-2; CARBOCYANINE; CELL NUCLEUS ANTIGEN; CY5.5 CYANINE DYE; GLIAL FIBRILLARY ACIDIC PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NERVE PROTEIN; NEURONAL NUCLEAR ANTIGEN NEUN, HUMAN; PEPTIDE;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; METABOLISM; MOUSE; PROTEIN TRANSPORT; RADIOASSAY; RAT; TRANSCYTOSIS; VASCULARIZATION;

ANIMALS; ANTIGENS, NUCLEAR; BLOOD-BRAIN BARRIER; BRAIN; CARBOCYANINES; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GLIAL FIBRILLARY ACIDIC PROTEIN; LDL-RECEPTOR RELATED PROTEIN 1; MICE; MICROSCOPY, FLUORESCENCE; NERVE TISSUE PROTEINS; PEPTIDES; PROTEIN TRANSPORT; RADIOLIGAND ASSAY; RATS; TRANSCYTOSIS;

MUS;

EID: 78650054460     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00930.x     Document Type: Article

References (56)

1. Roux F, Couraud PO. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell Mol Neurobiol. 2005; 25: 41-58.
2. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003; 3: 90-105, 51.
3. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2: 3-14.
4. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007; 6: 650-61.
5. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007; 24: 1733-44.
6. Dove A. Breaching the barrier. Nat Biotechnol. 2008; 26: 1213-5.
7. Demeule M, Regina A, Che C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008; 324: 1064-72.
8. Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008; 106: 1534-44.
9. Acarregui MJ, England KM, Richman JT, et al. Characterization of CD341 cells isolated from human fetal lung. Am J Physiol Lung Cell Mol Physiol. 2003; 284: L395-401.
10. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007; 117: 94-8.
11. Zhang C, An J, Strickland DK, et al. The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain. Am J Pathol. 2009; 174: 586-94.
12. Wilhelmus MM, Otte-Holler I, Van Triel JJ, et al. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol. 2007; 171: 1989-99.
13. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001; 108: 779-84.
14. Beisiegel U, Weber W, Ihrke G, et al. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989; 341: 162-4.
15. Strickland DK, Ashcom JD, Williams S, et al. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem. 1990; 265: 17401-4.
16. Regina A, Demeule M, Che C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008; 155: 185-97.
17. Abulrob A, Brunette E, Slinn J, et al. In vivo time domain optical imaging of renal ischemia-reperfusion injury: discrimination based on fluorescence lifetime. Mol Imaging. 2007; 6: 304-14.
18. Abulrob A, Brunette E, Slinn J, et al. Dynamic analysis of the blood-brain barrier disruption in experimental stroke using time domain in vivo fluorescence imaging. Mol Imaging. 2008; 7: 248-62.
19. Cisternino S, Rousselle C, Dagenais C, et al. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm Res. 2001; 18: 183-90.
20. Dagenais C, Rousselle C, Pollack GM, et al. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab. 2000; 20: 381-6.
21. Pickering M, Pickering BW, Murphy KJ, et al. Discrimination of cell types in mixed cortical culture using calcium imaging: a comparison to immunocytochemical labeling. J Neurosci Methods. 2008; 173: 27-33.
22. Moestrup SK, Schousboe I, Jacobsen C, et al. beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J Clin Invest. 1998; 102: 902-9.
23. Regina A, Demeule M, Che C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008; 155: 185-97.
24. Banks WA, Goulet M, Rusche JR, et al. Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J Pharmacol Exp Ther. 2002; 302: 1062-9.
25. Duvernoy H, Delon S, Vannson JL. The vascularization of the human cerebellar cortex. Brain Res Bull. 1983; 11: 419-80.
26. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res. 2006; 56: 246-52.
27. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000; 106: 1489-99.
28. Bu G, Maksymovitch EA, Nerbonne JM, et al. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J Biol Chem. 1994; 269: 18521-8.
29. Polavarapu R, Gongora MC, Yi H, et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood. 2007; 109: 3270-8.
30. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993; 11: 575-80.
31. Tooyama I, Kawamata T, Akiyama H, et al. Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain. Brain Res. 1995; 691: 235-8.
32. Wolf BB, Lopes MB, VandenBerg SR, et al. Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol. 1992; 141: 37-42.
33. Furian AF, Oliveira MS, Royes LF, et al. GM1 ganglioside induces vasodilation and increases catalase content in the brain. Free Radic Biol Med. 2007; 43: 924-32.
34. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx. 2005; 2: 54-62.
35. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007; 13: 1029-31.
36. Williams SE, Ashcom JD, Argraves WS, et al. A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem. 1992; 267: 9035-40.
37. Anderson CM, Howard A, Walters JR, et al. Taurine uptake across the human intestinal brush-border membrane is via two transporters: H(+)-coupled PAT1 (SLC36A1) and Na(+)- and Cl(-)-dependent TauT (SLC6A6). J Physiol. 2009; 587: 731-44.
38. Drain J, Bishop JR, Hajduk SL. Haptoglobin-related protein mediates trypanosome lytic factor binding to trypanosomes. J Biol Chem. 2001; 276: 30254-60.
39. Yamada K, Hashimoto T, Yabuki C, et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid {beta} peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem. 2008; 283: 34554-62.
40. Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008; 106: 1534-44.
41. Dolmer K, Gettins PG. Three complement-like repeats compose the complete alpha2-macroglobulin binding site in the second ligand binding cluster of the low density lipoprotein receptor-related protein. J Biol Chem. 2006; 281: 34189-96.
42. Wu SM, Boyer CM, Pizzo SV. The binding of receptor-recognized alpha2-macroglobulin to the low density lipoprotein receptor-related protein and the alpha2M signaling receptor is decoupled by oxidation. J Biol Chem. 1997; 272: 20627-35.
43. Liu Z, Winters M, Holodniy M, et al. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl. 2007; 46: 2023-7.
44. Warshawsky I, Herz J, Broze GJ Jr, et al. The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem. 1996; 271: 25873-9.
45. Vives E. Cellular uptake [correction of utake] of the Tat peptide: an endocytosis mechanism following ionic interactions. J Mol Recognit. 2003; 16: 265-71.
46. Rusnati M, Urbinati C, Caputo A, et al. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem. 2001; 276: 22420-5.
47. Gosselet F, Candela P, Sevin E, et al. Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res. 2009; 1249: 34-42.
48. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev. 2002; 54: 1343-52.
49. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003; 9: 907-13.
50. Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. AAPS J. 2008; 10: 455-72.
51. Wender PA, Mitchell DJ, Pattabiraman K, et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA. 2000; 97: 13003-8.
52. Suzuki T, Futaki S, Niwa M, et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem. 2002; 277: 2437-43.
53. Gaillard PJ, Visser CC, De Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv. 2005; 2: 299-309.
54. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2: 3-14.
55. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1999; 1: 55-68.
56. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000; 44: 235-49.